Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 20/20 | 0.78 |
| ▸ | GIPR | P48546 | 13/20 | 0.78 |
| ▸ | VIPR2 | P41587 | 4/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.78 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.78 |
| ▸ | DUSP2 | Q05923 | 1/20 | 0.78 |
| ▸ | GLP1R | P43220 | 2/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2667967 | 1.00 | GCGR (0.78) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL3245274 | 0.92 | GCGR (0.76) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL2659100 | 0.92 | GCGR (0.76) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL13356630 | 0.89 | GCGR (0.69) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL3250710 | 0.89 | GCGR (0.69) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| Mk-0893 SCHEMBL2355321 | 0.88 | GCGR (1.00) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| Mk-0893 SCHEMBL29363684 | 0.88 | GCGR (1.00) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| Mk-0893 SCHEMBL675777 | 0.88 | GCGR (1.00) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL3256419 | 0.87 | GCGR (0.76) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL9071367 | 0.87 | GCGR (0.76) | GCGRGIPRVIPR2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625938-B2 | Substituted pyrazoles, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625938-B2 | Substituted pyrazoles, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080108620-A1 | Substituted Pyrazoles, Compositions Containing such Compounds and Methods of Use | MERCK & CO., INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108620-A1 | Substituted Pyrazoles, Compositions Containing such Compounds and Methods of Use | MERCK & CO., INC. (US) | 2008-05-08 | — | — | US | disclosed |
| WO-2006014618-A2 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108620-A1 | Substituted Pyrazoles, Compositions Containing such Compounds and Methods of Use | GLP1R, GCGR, GPR119 | GCGR 2/4885GIPR 4/4885VIPR2 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.